Clinicopathological and molecular characterisation of "multiple-classifier" endometrial carcinomas
Smit, Vincent THBM
McAlpine, Jessica N.
Brucker, Sara Y.
Carlson, Joseph W.
Rau, Tilman T.
Soslow, Robert A.
Harrison, Beth T.
Church, David N.
Gilks, C. Blake
MetadataShow full item record
Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in recent years due to its prognostic utility and potential to predict benefit from adjuvant treatment. While most ECs can be classified based on a single classifier (POLE exonuclease domain mutations – POLEmut, MMR deficiency – MMRd, p53 abnormal – p53abn), a small but clinically relevant group of tumours harbour more than one molecular classifying feature and are referred to as ‘multiple‐classifier’ ECs. We aimed to describe the clinicopathological and molecular features of multiple‐classifier ECs with abnormal p53 (p53abn). Within a cohort of 3518 molecularly profiled ECs, 107 (3%) tumours displayed p53abn in addition to another classifier(s), including 64 with MMRd (MMRd–p53abn), 31 with POLEmut (POLEmut–p53abn), and 12 with all three aberrations (MMRd–POLEmut–p53abn). MMRd–p53abn ECs and POLEmut–p53abn ECs were mostly grade 3 endometrioid ECs, early stage, and frequently showed morphological features characteristic of MMRd or POLEmut ECs. 18/28 (60%) MMRd–p53abn ECs and 7/15 (46.7%) POLEmut–p53abn ECs showed subclonal p53 overexpression, suggesting that TP53 mutation was a secondary event acquired during tumour progression. Hierarchical clustering of TCGA ECs by single nucleotide variant (SNV) type and somatic copy number alterations (SCNAs) revealed that MMRd–p53abn tumours mostly clustered with single‐classifier MMRd tumours (20/23) rather than single‐classifier p53abn tumours (3/23), while POLEmut–p53abn tumours mostly clustered with single‐classifier POLEmut tumours (12/13) and seldom with single‐classifier p53abn tumours (1/13) (both p ≤ 0.001, chi‐squared test). Finally, the clinical outcome of patients with MMRd–p53abn and POLEmut–p53abn ECs [stage I 5‐year recurrence‐free survival (RFS) of 92.2% and 94.1%, respectively] was significantly different from single‐classifier p53abn EC (stage I RFS 70.8%, p = 0.024 and p = 0.050, respectively). Our results support the classification of MMRd–p53abn EC as MMRd and POLEmut–p53abn EC as POLEmut. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Is part ofJournal of Pathology, 2019, vol. 250, núm. 3, p. 312-322
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by, (c) León-Castillo et al., 2019
Showing items related by title, author, creator and subject.
Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups Bosse, Tjalling; Nout, Remi; McAlpine, Jessica N.; McConechy, Melissa; Britton, Heidi; Hussein, Yaser; Gonzalez, Carlene; Ganesan, Raji; Steele, Jane C.; Harrison, Beth T.; Oliva, Esther; Vidal, August; Matias-Guiu, Xavier; Abu-Rustum, Nadeem R.; Levine, Douglas A.; Gilks, C. Blake; Soslow, Robert A. (Wolters Kluwer Health, 2018)Our aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on ...
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations Murali, Rajmohan; Davidson, Ben; Fadare, Oluwole; Carlson, Joseph A.; Crum, Christopher; Gilks, C. Blake; Irving, Julie A.; Malpica, Anais; Matias-Guiu, Xavier; McCluggage, W. Glenn; Mittal, Khush; Oliva, Esther; Parkash, Vinita; Rutgers, Joanne; Staats, Paul; Stewart, Colin; Tornos, Carmen; Soslow, Robert A. (Lippincott, Williams & Wilkins, 2019)This review of challenging diagnostic issues concerning high-grade endometrial carcinomasisderivedfromtheauthors’ reviewoftheliteraturefollowedbydiscussionsatthe Endometrial Cancer Workshop sponsored by the International ...
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists Soslow, Robert A.; Tornos, Carmen; Park, Kay J.; Malpica, Anais; Matias-Guiu, Xavier; Oliva, Esther; Parkash, Vinita; Carlson, Joseph A.; McCluggage, W. Glenn; Gilks, C. Blake (Lippincott, Williams & Wilkins, 2019)In this review, we sought to address 2 important issues in the diagnosis of endometrial carcinoma: how to grade endometrial endometrioid carcinomas and how to incorporate the 4 genomic subcategories of endometrial carcinoma, ...